Trial Profile

Glimepiride monotherapy vs. combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linagliptin (Primary) ; Glimepiride
Indications Diabetes mellitus
Focus Therapeutic Use
Acronyms GLIMLINA

Most Recent Events

25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
13 Jul 2020 Results published in the Diabetes Care Journal.
16 Jun 2020 Primary endpoint (Mean amplitude of glycaemic excursions (MAGE)) has not been met, according to results presented at the 80th Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com